Ovarian and Uterine Cancer, Brain Tumor, Biliary Tract and Pancreatic Cancer, and Hematologic Malignancy Centers Newly Added; Data Refined Using the International Classification of Diseases for Oncology

“Published to Enhance Transparency and Improve Quality of Care; We Aim to Lead Global Cancer Treatment Through a Standardized System”

▲ President Si Yeol Song of AMC Cancer Institute (left) and medical staff of the AMC Cancer Institute discuss treatment outcomes and future operational plans for each specialized cancer center.

“More than 37,000 Cancer Patients Receive Treatment at Asan Medical Center Each Year”

“One in Five Pancreatic Cancer Patients in Korea Is Treated at Asan Medical Center, with More Than Half Diagnosed at Stage IV”

“Over 2,000 Brain Tumor Surgeries Performed Annually, Among the Highest Volumes in Korea”

“Despite 58 Percent of Ovarian Cancer Patients Presenting with Advanced Stage III or IV Disease, the 30 Day Postoperative Mortality Rate Remains Below 0.1 Percent”

“More Than 98 Percent of Hematologic Malignancy Patients Survive Beyond 100 Days Following Autologous Hematopoietic Stem Cell Transplantation”

<Excerpt from the 2025 Asan Medical Center Medical Quality Assessment Report for Cancer Care>

AMC Cancer Institute, which treats one in eight cancer patients in Korea, has published a report analyzing its cancer treatment outcomes based on the International Classification of Diseases for Oncology (ICD O).

The Cancer Institute recently released its Cancer Care Medical Quality Assessment Report (Outcomes Book), presenting treatment outcomes from seven specialized centers: the Ovarian and Uterine Cancer Center, Brain Tumor Center, Biliary Tract and Pancreatic Cancer Center, Colorectal Cancer Center, Gastric Cancer Center, Breast Cancer Center, and Hematologic Malignancy and Bone Marrow Transplant Center.

The report serves as a valuable resource for providing cancer patients with objective information on the Cancer Institute’s treatment outcomes, thereby enhancing trust in the hospital. It is also used to maintain and further advance Asan Medical Center’s patient centered cancer care system and commitment to excellence in oncology.

Now in its third edition, the Cancer Care Medical Quality Assessment Report presents treatment outcome data through 2024 for seven cancer types, including colorectal, breast, and gastric cancers, which are among the most common cancers in Korea, as well as newly added ovarian and uterine cancers, brain tumors, biliary tract and pancreatic cancers, and hematologic malignancies.

The first report, published in 2024, featured treatment outcomes for five of the most prevalent cancers in Korea: liver, colorectal, gastric, breast, and lung cancers. The second edition, released in 2025, expanded its scope to include genitourinary cancers such as bladder, kidney, and prostate cancers.

The report includes quantitative indicators such as the nation’s largest volume of multidisciplinary cancer care consultations and cancer surgeries and procedures, as well as world-class qualitative indicators, including five year survival rates by stage, postoperative complication rates, and length of hospital stay.

In particular, AMC Cancer Institute further advanced its data framework this year by incorporating the ICD O 3 Histology Classification System, an international oncology classification standard, in addition to the conventional diagnosis code based system. This enhancement enables the data system to more accurately reflect the histological characteristics and clinical information of individual cancers and provides a foundation for expanding outcome analyses to a broader range of cancer types in the future.

The latest report also includes specialized indicators published exclusively by AMC Cancer Institute. These include the number of fertility preserving treatments performed for patients with early stage cervical and endometrial cancers, the cumulative number of hematopoietic stem cell transplantations performed since Asan Medical Center’s opening, and the proportion of highly complex pancreatic cancer surgeries involving vascular reconstruction or tumors invading major arteries and veins.

These indicators offer a comprehensive view of AMC Cancer Institute’s clinical volume, expertise in managing highly complex cases, and patient centered care system that prioritizes not only treatment outcomes but also patients’ quality of life before and after treatment.

The report also highlights the history and current status of AMC Cancer Institute, including the Multidisciplinary Cancer Care Center, the first of its kind in Korea established in 2006; the Life Care Center for Cancer Patients and Palliative Care Center, which focus on improving patients’ quality of life; and advanced precision medicine programs such as AMC Cancer Institute Data Center, Center for Personalized Cancer Medicine, CAR T-Cell Therapy Center, and Theranostics Center.

The Cancer Care Medical Quality Assessment Report is available on the AMC Cancer Institute website. In addition to the Korean edition, an English version will also be published.

President Si Yeol Song of AMC Cancer Institute (Professor of Department of Radiation Oncology) said, “The Cancer Care Medical Quality Assessment Report is published on a regular basis to enhance transparency in cancer care and improve the quality of cancer care. We plan to further expand the range of cancer types covered and systematically develop and refine treatment outcome data across all cancer centers at Asan Medical Center. Through a patient centered and standardized cancer care system, we will continue to lead advances in cancer treatment not only in Korea but around the world.”